Kalmar Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Kalmar Investments’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$7.85M	Sell	118,827 -274,057	-70%	-$18M	1.77%	12
2016 Q4	$24.9M	Sell	392,884 -48,045	-11%	-$3.03M	1.28%	18
2016 Q3	$28.1M	Sell	440,929 -6,813	-2%	-$500K	1.28%	20
2016 Q2	$33.3M	Sell	447,742 -4,418	-1%	-$328K	1.47%	18
2016 Q1	$30.2M	Sell	452,160 -17,745	-4%	-$1.08M	1.24%	26
2015 Q4	$31.8M	Sell	469,905 -19,207	-4%	-$1.19M	0.78%	54
2015 Q3	$26.1M	Sell	489,112 -77,726	-14%	-$4.72M	0.61%	65
2015 Q2	$35.7M	Sell	566,838 -130,116	-19%	-$7.1M	0.68%	60
2015 Q1	$33.5M	Buy	696,954 +233,839	+50%	+$8.96M	0.62%	65
2014 Q4	$15.4M	Buy	+463,115	New	+$15.1M	0.29%	107

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Kalmar Investments's LGND Position: Q1 2017 in Review

Kalmar Investments reduced its Ligand Pharmaceuticals (LGND) stake by 70% in Q1 2017, selling an estimated $18M and leaving 118,827 shares worth $7.85M. The position accounts for 1.77% of the portfolio, ranked #12.

Kalmar Investments first reported a position in LGND in Q4 2014 and has held it in 10 quarters since. The position peaked at $35.7M in Q2 2015. 257 funds tracked by Wall St. Rank hold LGND as of Q1 2017.

Kalmar Investments held 118,827 shares of Ligand Pharmaceuticals worth $7.85M as of Q1 2017.
Kalmar Investments sold 274,057 Ligand Pharmaceuticals shares in Q1 2017, an estimated $18M.
Ligand Pharmaceuticals made up 1.77% of Kalmar Investments's portfolio in Q1 2017, its #12 holding.
Kalmar Investments first reported a position in Ligand Pharmaceuticals in Q4 2014 and has held it in 10 quarters since.
Kalmar Investments's Ligand Pharmaceuticals position peaked at $35.7M in Q2 2015.
257 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2017.

Based on Kalmar Investments's 13F filing for Q1 2017, filed 26 Apr 2017.